Kiromic BioPharma, Inc. (KRBP) 


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Kiromic BioPharma, Inc. ("Kiromic” or "the Company") (NASDAQ: KRBP). The investigation concerns whether Kiromic and certain of its officers and/or directors have violated federal securities laws.


On or around October 16, 2020, Kiromic conducted its initial public offering, selling 1.25 million shares of common stock priced at $12.00 per share.  Then, on July 16, 2021, Kiromic issued a press release disclosing that, following the May 2021 submission of two Investigational New Drug Applications (“INDs”) to the U.S. Food and Drug Administration (“FDA”) “for the first-in-human off-the-shelf allogeneic CAR-T for Solid Tumors”, the “FDA returned with comments on the Company’s allogeneic CAR-T products with respect to . . . Tracing of all reagents used in manufacturing . . . Flow chart of manufacturing processes . . . [and]  Certificate of Analysis (COA) for the Company’s CAR-T products (allogeneic CAR-T).”  On this news, Kiromic’s stock price fell $0.63 per share, or 16.76%, to close at $3.13 per share on July 16, 2021.


If you are aware of any facts relating to this investigation, or purchased Kiromic shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.